| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.
|
Int J Clin Oncol
|
2011
|
5.39
|
|
2
|
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
|
J Clin Oncol
|
2003
|
2.97
|
|
3
|
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer.
|
Nat Genet
|
2008
|
2.89
|
|
4
|
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
|
Lancet Oncol
|
2010
|
2.73
|
|
5
|
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.
|
Int J Clin Oncol
|
2015
|
2.70
|
|
6
|
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
|
J Clin Oncol
|
2013
|
2.26
|
|
7
|
Efficacy of clinical pathway for the management of mucosal gastric carcinoma treated with endoscopic submucosal dissection using an insulated-tip diathermic knife.
|
Intern Med
|
2004
|
1.93
|
|
8
|
Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue.
|
J Gastroenterol
|
2006
|
1.75
|
|
9
|
Seronegative alpha-fetoprotein-producing early gastric cancer treated with endoscopic mucosal resection and additional surgery.
|
Intern Med
|
2004
|
1.45
|
|
10
|
Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans.
|
Cancer Prev Res (Phila)
|
2009
|
1.31
|
|
11
|
Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice.
|
Am J Physiol Gastrointest Liver Physiol
|
2008
|
1.27
|
|
12
|
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
|
Jpn J Clin Oncol
|
2004
|
1.26
|
|
13
|
Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice.
|
Am J Physiol Gastrointest Liver Physiol
|
2009
|
1.21
|
|
14
|
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
|
Cancer Sci
|
2011
|
1.17
|
|
15
|
Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers.
|
J Clin Gastroenterol
|
2006
|
1.08
|
|
16
|
Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats.
|
Hepatology
|
2006
|
1.06
|
|
17
|
Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.
|
Jpn J Clin Oncol
|
2009
|
1.05
|
|
18
|
Granular cell tumor occurring in the sigmoid colon treated by endoscopic mucosal resection using a transparent cap (EMR-C).
|
J Gastroenterol
|
2003
|
1.05
|
|
19
|
MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications.
|
Eur J Cancer
|
2008
|
1.03
|
|
20
|
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
|
Cancer Sci
|
2011
|
1.03
|
|
21
|
The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine.
|
J Clin Biochem Nutr
|
2011
|
1.03
|
|
22
|
Gastric cancer concomitant with inflammatory fibroid polyp treated with endoscopic mucosal resection using an insulation-tip diathermic knife.
|
Intern Med
|
2003
|
0.98
|
|
23
|
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
|
J Gastroenterol
|
2011
|
0.96
|
|
24
|
Current status of Kampo (Japanese herbal) medicines in Japanese clinical practice guidelines.
|
Complement Ther Med
|
2008
|
0.96
|
|
25
|
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
|
Anticancer Drugs
|
2008
|
0.94
|
|
26
|
Prevalence and characteristics of asymptomatic excessive transmural injury after radiofrequency catheter ablation of atrial fibrillation.
|
Heart Rhythm
|
2011
|
0.94
|
|
27
|
Neoplastic transformation and induction of H+,K+ -adenosine triphosphatase by N-methyl-N'-nitro-N-nitrosoguanidine in the gastric epithelial RGM-1 cell line.
|
In Vitro Cell Dev Biol Anim
|
2007
|
0.92
|
|
28
|
NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin.
|
Cancer Sci
|
2013
|
0.92
|
|
29
|
Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
|
Jpn J Clin Oncol
|
2010
|
0.91
|
|
30
|
Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatin.
|
Gastric Cancer
|
2000
|
0.91
|
|
31
|
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.
|
Anticancer Drugs
|
2006
|
0.91
|
|
32
|
The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
|
Oncol Res
|
2013
|
0.90
|
|
33
|
Hepatocyte-specific deletion of heme oxygenase-1 disrupts redox homeostasis in basal and oxidative environments.
|
Tohoku J Exp Med
|
2008
|
0.90
|
|
34
|
Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
|
Int J Cancer
|
2013
|
0.90
|
|
35
|
Gastric acid induces mitochondrial superoxide production and lipid peroxidation in gastric epithelial cells.
|
J Gastroenterol
|
2011
|
0.89
|
|
36
|
Effectiveness of an endoscopic biopsy procedure using EUS-FNA and EMR-C for diagnosing adenocarcinoma arising from ectopic pancreas: two case reports and a literature review.
|
Intern Med
|
2014
|
0.89
|
|
37
|
Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model.
|
Int J Cancer
|
2013
|
0.89
|
|
38
|
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
|
Gastric Cancer
|
2011
|
0.89
|
|
39
|
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial.
|
Jpn J Clin Oncol
|
2004
|
0.89
|
|
40
|
Multiple synchronous early gastric carcinoma with seven lesions.
|
J Gastroenterol
|
2003
|
0.89
|
|
41
|
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
|
J Cancer Res Clin Oncol
|
2014
|
0.88
|
|
42
|
Risk factors for submucosal and lymphovascular invasion in gastric cancer looking indicative for endoscopic submucosal dissection.
|
Gastric Cancer
|
2013
|
0.88
|
|
43
|
Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.
|
Jpn J Clin Oncol
|
2007
|
0.86
|
|
44
|
Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70.
|
Digestion
|
2007
|
0.86
|
|
45
|
[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].
|
Gan To Kagaku Ryoho
|
2008
|
0.86
|
|
46
|
Diagnosis of drug-induced liver injury in Japanese patients by criteria of Consensus Meetings in Europe.
|
Hepatol Res
|
2003
|
0.85
|
|
47
|
Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study.
|
Gastric Cancer
|
2002
|
0.85
|
|
48
|
Lansoprazole inhibits mitochondrial superoxide production and cellular lipid peroxidation induced by indomethacin in RGM1 cells.
|
J Clin Biochem Nutr
|
2011
|
0.85
|
|
49
|
Unusual metastasis of hepatocellular carcinoma to the esophagus.
|
Intern Med
|
2005
|
0.85
|
|
50
|
[Malignant lymphoma with submucosal invasion in the terminal ileum diagnosed with colonoscopy and examined by endoscopic ultrasonography].
|
Nihon Shokakibyo Gakkai Zasshi
|
2004
|
0.85
|
|
51
|
Bisphosphonate-induced gastrointestinal mucosal injury is mediated by mitochondrial superoxide production and lipid peroxidation.
|
J Clin Biochem Nutr
|
2012
|
0.83
|
|
52
|
Cellular membrane fluidity measurement by fluorescence polarization in indomethacin-induced gastric cellular injury in vitro.
|
J Gastroenterol
|
2007
|
0.83
|
|
53
|
NSAIDs and acidic environment induce gastric mucosal cellular mitochondrial dysfunction.
|
Digestion
|
2012
|
0.83
|
|
54
|
[A case of Cronkhite-Canada syndrome associated with cholangiocellular carcinoma].
|
Nihon Shokakibyo Gakkai Zasshi
|
2005
|
0.83
|
|
55
|
Alcohol is an oxidative stressor for gastric epithelial cells: detection of superoxide in living cells.
|
J Clin Biochem Nutr
|
2013
|
0.82
|
|
56
|
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
|
Med Oncol
|
2011
|
0.81
|
|
57
|
A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma.
|
Radiat Oncol
|
2013
|
0.81
|
|
58
|
Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis.
|
World J Gastroenterol
|
2013
|
0.81
|
|
59
|
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine.
|
Eur J Cancer
|
2004
|
0.81
|
|
60
|
E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
|
Clin Cancer Res
|
2007
|
0.81
|
|
61
|
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
|
Jpn J Clin Oncol
|
2011
|
0.80
|
|
62
|
Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
|
Jpn J Clin Oncol
|
2007
|
0.80
|
|
63
|
Peroxiredoxin I protects gastric mucosa from oxidative injury induced by H. pylori infection.
|
J Gastroenterol Hepatol
|
2007
|
0.80
|
|
64
|
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.80
|
|
65
|
Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.
|
Med Oncol
|
2014
|
0.79
|
|
66
|
EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
|
Int J Cancer
|
2011
|
0.79
|
|
67
|
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
|
Jpn J Clin Oncol
|
2005
|
0.79
|
|
68
|
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.78
|
|
69
|
[A retrospective analysis of cetuximab or panitumumab monotherapy for KRAS wild-type metastatic colorectal cancer in clinical practice].
|
Gan To Kagaku Ryoho
|
2015
|
0.78
|
|
70
|
Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: a multicenter, prospective, observational study.
|
J Pain Symptom Manage
|
2004
|
0.78
|
|
71
|
Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignancies.
|
J Pain Symptom Manage
|
2006
|
0.78
|
|
72
|
Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
|
Int J Cancer
|
2008
|
0.78
|
|
73
|
[A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin].
|
Gan To Kagaku Ryoho
|
2014
|
0.78
|
|
74
|
Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR.
|
Anticancer Res
|
2013
|
0.78
|
|
75
|
A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer.
|
Cancer Chemother Pharmacol
|
2005
|
0.78
|
|
76
|
Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study.
|
Int J Clin Oncol
|
2014
|
0.77
|
|
77
|
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
|
Invest New Drugs
|
2013
|
0.77
|
|
78
|
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
|
Gastric Cancer
|
2013
|
0.77
|
|
79
|
Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer.
|
BMC Cancer
|
2013
|
0.77
|
|
80
|
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
81
|
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
|
Jpn J Clin Oncol
|
2008
|
0.76
|
|
82
|
Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis.
|
Intern Med
|
2016
|
0.76
|
|
83
|
Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.
|
Onkologie
|
2013
|
0.75
|
|
84
|
Timing of significant adverse events is essential information during early development of new drugs.
|
Int J Clin Oncol
|
2006
|
0.75
|
|
85
|
A Rare Case of Colonic Leiomyosarcoma in Association with Ulcerative Colitis.
|
Intern Med
|
2016
|
0.75
|
|
86
|
Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer?
|
Gastric Cancer
|
2012
|
0.75
|
|
87
|
How should oncologists face complementary and alternative medicine?
|
Jpn J Clin Oncol
|
2008
|
0.75
|
|
88
|
Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion.
|
Gastrointest Cancer Res
|
2007
|
0.75
|
|
89
|
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).
|
Jpn J Clin Oncol
|
2003
|
0.75
|
|
90
|
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
|
Gan To Kagaku Ryoho
|
2007
|
0.75
|
|
91
|
Extragonadal retroperitoneal embryonal carcinoma successfully treated with chemotherapy.
|
Intern Med
|
2003
|
0.75
|
|
92
|
[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].
|
Gan To Kagaku Ryoho
|
2004
|
0.75
|
|
93
|
[Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer].
|
Gan To Kagaku Ryoho
|
2003
|
0.75
|
|
94
|
[Standard chemotherapy for colonic neoplasms].
|
Nihon Naika Gakkai Zasshi
|
2007
|
0.75
|
|
95
|
Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers.
|
Drug Metab Pharmacokinet
|
2013
|
0.75
|
|
96
|
[Revision of the training curriculum of Japan Society of Gastroenterology: gastroenterologist's role and professionalism].
|
Nihon Shokakibyo Gakkai Zasshi
|
2013
|
0.75
|
|
97
|
Tizanidine-induced hypotension in patients with liver cirrhosis.
|
Eur J Clin Pharmacol
|
2008
|
0.75
|
|
98
|
High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
|
Oncology
|
2009
|
0.75
|
|
99
|
Impact of solute carrier family 29 member 1 (SLC29A1) single nucleotide polymorphisms on mRNA expression in peripheral blood mononuclear cells.
|
Biol Pharm Bull
|
2012
|
0.75
|
|
100
|
[A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
|
Gan To Kagaku Ryoho
|
2004
|
0.75
|
|
101
|
Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.
|
Intern Med
|
2004
|
0.75
|
|
102
|
[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].
|
Nihon Rinsho
|
2011
|
0.75
|
|
103
|
Collagenous sprue diagnosed by double balloon endoscopy.
|
Dig Endosc
|
2012
|
0.75
|
|
104
|
[Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer].
|
Gan To Kagaku Ryoho
|
2004
|
0.75
|